SCHEMBL4190840

SCHEMBL4190840

C=C(C)C(=O)OC(COc1ccccc1-c1ccccc1)COc1c(C)cc(-c2cc(C)c(OCC(COc3ccccc3-c3ccccc3)OC(=O)C(=C)C)c(C)c2)cc1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.46
LMNA P02545 4/20 0.40
TDP1 Q9NUW8 3/20 0.40
MAPK1 P28482 3/20 0.40
ALDH1A1 P00352 4/20 0.39
HTT P42858 3/20 0.39
ADRB2 P07550 2/20 0.39
ADRB1 P08588 1/20 0.39
KDM4E B2RXH2 7/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
USP2 O75604 1/20 0.38
MAPT P10636 1/20 0.38
PPARG P37231 1/20 0.37
PPARA Q07869 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
PKM P14618 1/20 0.37
RXRA P19793 1/20 0.37
RXRB P28702 1/20 0.37
RXRG P48443 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4202053 0.89 L3MBTL1 (0.46) L3MBTL1LMNATDP1MAPK1ALDH1A1
SCHEMBL4193703 0.89 L3MBTL1 (0.46) L3MBTL1LMNATDP1MAPK1ALDH1A1
SCHEMBL4198613 0.85 THRB (0.43) LMNAMAPTPPARGPPARA
SCHEMBL21842315 0.85 L3MBTL1 (0.43) L3MBTL1LMNATDP1MAPK1ALDH1A1
SCHEMBL4197860 0.85 L3MBTL1 (0.43) L3MBTL1LMNATDP1MAPK1ALDH1A1
SCHEMBL4195597 0.85 L3MBTL1 (0.43) L3MBTL1LMNATDP1MAPK1ALDH1A1
SCHEMBL4197809 0.84 L3MBTL1 (0.48) L3MBTL1LMNATDP1MAPK1ALDH1A1
SCHEMBL4197210 0.84 MAPT (0.41) LMNASMN1; SMN2MAPTPPARGPPARA
SCHEMBL4186157 0.84 L3MBTL1 (0.42) L3MBTL1LMNATDP1MAPK1ALDH1A1
SCHEMBL4202732 0.84 NR2E1 (0.41) LMNATDP1MAPK1ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1627867-B1 (METH)ACRYLIC ESTER COMPOUND AND USE THEREOF MITSUI CHEMICALS INC (JP) 2016-01-20 EP disclosed
US-7534909-B2 (Meth) acrylic ester compound and use thereof MITSUI CHEMICALS, INC. (JP) 2009-05-19 US disclosed
US-20070078198-A1 (Meth) acrylic ester compound and use thereof MITSUI CHEMICALS, INC. (JP) 2007-04-05 US disclosed
EP-1627867-A1 (METH)ACRYLIC ESTER COMPOUND AND USE THEREOF Mitsui Chemicals, Inc. (JP) 2006-02-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078198-A1 (Meth) acrylic ester compound and use thereof METTL14, PAM, TAS2R41 L3MBTL1 2124/4885LMNA 4549/4885TDP1 2459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.